Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024
RANCHO CUCAMONGA, CA / ACCESSWIRE / April 30, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2024 ended March 31, 2024, after the market closes on Wednesday, May 8, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
加利福尼亞州庫卡蒙格牧場/ACCESSWIRE/2024年4月30日/Amphastar Pharmicals, Inc.（納斯達克股票代碼：AMPH）宣佈，該公司將在2024年5月8日星期三收盤後發佈截至2024年3月31日的2024年第一季度業績，並將於太平洋時間下午2點舉行電話會議討論其財務業績。
To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.
要接聽電話會議，請撥打免費電話 877-407-0989；如果要撥打國際電話，請在會議開始前十分鐘撥打 201-389-0921。
The call can also be accessed on the Investors page on the Company's website . The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conference call.
也可以在公司網站的 “投資者” 頁面上訪問該電話會議。電話會議直播的重播將在電話會議直播結束後的24小時內在我們公司的網站上播出。
Company Information
公司信息
Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at .
Amphastar是一家生物製藥公司，主要專注於開發、製造、營銷和銷售技術上具有挑戰性的仿製和專有注射劑、吸入和鼻內產品。此外，該公司還銷售胰島素原料藥產品。該公司的大多數成品用於醫院或緊急護理臨床環境，主要通過團體採購組織和藥品批發商簽約和分銷。更多信息和資源可在以下網址獲得。
Forward Looking Statements
前瞻性陳述
All statements in this press release and in the webcast referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the prospective benefits of the acquisition of BAQSIMI, and other future events, including potential contingent consideration amounts and terms related to the acquisition of BAQSIMI, the anticipated benefits of BAQSIMI to our product portfolio, Amphastar's commitment to strategically maximizing the commercial potential of BAQSIMI, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 29, 2024. In particular, there can be no guarantee that the acquisition of BAQSIMI will be beneficial to our business, that any event, change or other circumstance could cause the results of the acquisition and integration of BAQSIMI into our product portfolio to differ from Amphastar's expectation, that all or any of the contingent consideration will be payable on the terms described herein or at all, or that Amphastar can reliably predict the impact of BAQSIMI on its financial results or financial guidance. You can locate these reports through our website at and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the webcast referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
本新聞稿和上述網絡直播中所有非歷史陳述均爲前瞻性陳述，除其他外，包括與我們對未來財務業績和業務趨勢的預期、我們的未來增長、產品的銷售和營銷、市場規模和擴張、產品組合、產品開發、FDA申報或批准時間（包括ANP的DMF）、產品發佈時間、收購以及與我們的產品線相關的其他事項相關的陳述候選產品，時機以及臨床試驗結果，收購BAQSIMI的潛在好處，以及其他未來事件，包括與收購 BAQSIMI 相關的潛在或有對價金額和條款，BAQSIMI 的預期好處 在我們的產品組合中，Amphastar承諾從戰略上最大限度地提高BAQSIMI的商業潛力，以及其他未來的事件。這些陳述不是事實，而是基於Amphastar的歷史表現以及我們當前對業務、運營和其他類似或相關因素的預期、估計和預測。使用 “可能”、“可能”、“將”、“可以”、“應該”、“預測”、“潛在”、“繼續”、“期望”、“打算”、“計劃”、“項目”、“相信”、“估計” 等詞語以及其他類似或相關的表述來識別這些前瞻性陳述，儘管並非所有前瞻性陳述都包含這些詞語。您不應過分依賴前瞻性陳述，因爲前瞻性陳述涉及已知和未知的風險、不確定性和假設，這些假設難以或不可能預測，在某些情況下甚至超出了Amphastar的控制範圍。由於多種因素，包括Amphastar向美國證券交易委員會提交的文件中描述的因素，包括我們在2024年2月29日向美國證券交易委員會提交的截至2023年12月31日年度的10-K表年度報告中描述的實際業績可能與前瞻性陳述中的業績存在重大差異。特別是，無法保證收購BAQSIMI 將有利於我們的業務，任何事件、變更或其他情況都可能導致收購BAQSIMI並將其整合到我們的產品組合中的結果與Amphastar的預期有所不同，所有或任何或有對價將按此處描述的條款支付或根本沒有支付，或者Amphastar可以可靠地預測BAQSIMI的影響 關於其財務業績或財務指導。您可以通過我們的網站和美國證券交易委員會的網站www.sec.gov找到這些報告。本新聞稿中的前瞻性陳述僅代表截至發佈之日。即使有新信息可用或後續事件導致我們的預期發生變化，Amphastar也沒有義務修改或更新本新聞稿或上述網絡直播中的信息或任何前瞻性陳述以反映未來的事件或情況。
Contact:
Bill Peters
Chief Financial Officer
(909) 476-3416
聯繫人：
比爾·彼得斯
首席財務官
(909) 476-3416
SOURCE: Amphastar Pharmaceuticals, Inc.
來源：Amphastar 製藥公司
譯文內容由第三人軟體翻譯。